Over 90% of United States and Canadian children and adolescents with cancer are enrolled in Children's Oncology Group (COG) clinical trials with no racial, ethnic or geographic bias to registration, allowing for near- population-based clinical, translational and basic research. Clinical trials conducted by COG and its antecedent organizations have played a major role in these advances and will continue to drive the improvements projected to come in the next decade. The biospecimens collected during these clinical treatment trials are crucial to their success. These biospecimens are sent to centralized laboratories for clinical testing and banking for future research use. The Biopathology Center (BPC) is part of the Research Institute at Nationwide Children's Hospital in Columbus, Ohio and houses the COG Solid Tissue Bank as well as the COG ALL Molecular Reference Laboratory and Bank. The COG AML Reference Laboratory and Bank is located at the Fred Hutchinson Cancer Research Center Seattle, Washington. Currently, the BPC is federally funded to serve several clients (including the Pediatric Division of the Cooperative Human Tissue Network [pCHTN], and the biobanking efforts of the Gynecologic Oncology Group [GOG], the Childhood Cancer Survivor Study [CCSS], and the Cancer Therapy Evaluation Program [CTEP]). To accomplish this, the banks continue to work with the aims of the original grant submission in 2004. 1. Establish collection, storage and quality control procedures for tissue banking in pediatric cancer patients that are near-population-based. 2. Ensure proper storage and quality control procedures for pediatric tissue bank biospecimens that promote outstanding retrospective translational research. 3. Ensure proper administration of tissue bank resources to facilitate investigator access to biospecimens. 4. Promote linkage of tissue bank resources to existing demographic, clinical, and biological, treatment and outcome data. 5. Optimize utilization of finite tissue bank resources utilizing emerging technologies.

Public Health Relevance

Today, over 80% of children with cancer are expected to be cured, with an approximately 50% decrease in mortality rate between 1975 and 2006. Five-year survival rates for acute myeloid leukemia (AML) and neuroblastoma have seen vast improvements. AML survival increased from under 50% to 60% and neuroblastoma survival rose from 65% to 75%. The higher survival rates of patients with acute lymphoblastic leukemia (ALL) improved from 86.8% to 89.0%. COG research has played a major role in improvements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
7U24CA114766-07
Application #
8337743
Study Section
Special Emphasis Panel (ZCA1-SRLB-5 (M1))
Program Officer
Lubensky, Irina
Project Start
2005-08-03
Project End
2014-03-31
Budget Start
2012-06-21
Budget End
2013-03-31
Support Year
7
Fiscal Year
2012
Total Cost
$1,329,162
Indirect Cost
$487,507
Name
Nationwide Children's Hospital
Department
Type
DUNS #
147212963
City
Columbus
State
OH
Country
United States
Zip Code
43205
Borinstein, Scott C; Barkauskas, Donald A; Bernstein, Mark et al. (2014) Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer 61:749-52
Khanna, Chand; Fan, Timothy M; Gorlick, Richard et al. (2014) Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res 20:4200-9
Laszlo, George S; Ries, Rhonda E; Gudgeon, Chelsea J et al. (2014) High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma 55:2817-21
Trimarchi, Thomas; Bilal, Erhan; Ntziachristos, Panagiotis et al. (2014) Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell 158:593-606
Fernandez, Christian A; Smith, Colton; Yang, Wenjian et al. (2014) HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124:1266-76
Moore, Andrew S; Alonzo, Todd A; Gerbing, Robert B et al. (2014) BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 61:647-52
Dandekar, Smita; Romanos-Sirakis, Eleny; Pais, Faye et al. (2014) Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br J Haematol 167:87-99
De Lorenzo, P; Moorman, A V; Pieters, R et al. (2014) Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. Leukemia 28:428-30
Gorlick, Sarah; Barkauskas, Donald A; Krailo, Mark et al. (2014) HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer 61:1558-64
Buitenkamp, Trudy D; Izraeli, Shai; Zimmermann, Martin et al. (2014) Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123:70-7

Showing the most recent 10 out of 68 publications